Trial ID or NCT#

NCT01777152

Status

not recruiting iconNOT RECRUITING

Purpose

This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.

Investigator(s)

Lauren Maeda, MD
Lauren Maeda, MD
Medical oncologist, Hematologist, Lymphoma specialist
Clinical Associate Professor, Medicine - Oncology Clinical Assistant Professor, Medicine - Hematology
Ranjana Advani
Ranjana Advani
Medical oncologist, Lymphoma specialist
Saul A. Rosenberg, MD, Professor of Lymphoma
Hans-Christoph Becker

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061